UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gene expression-based pharmacodynamic biomarkers: the beginning of a new era in biomarker-driven anti-tumor drug development

Current molecular medicine, 2010-08, Vol.10 (6), p.596-607

2010

Volltextzugriff (PDF)

433 Genomic predictors of therapeutic sensitivity to TAS-119, a selective inhibitor of Aurora-A kinase

European journal of cancer (1990), 2014-11, Vol.50, p.142-143

2014

Volltextzugriff (PDF)

438 Identification of Gene Expression Signature to Predict Anti-tumor Efficacy of MET/VEGFR Inhibitor, TAS-115

European journal of cancer (1990), 2012-11, Vol.48, p.136-136

2012

Volltextzugriff (PDF)

Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2

International journal of cancer, 2004-03, Vol.109 (2), p.238-246

2004

Volltextzugriff (PDF)

Advances in isolation and characterization of homogeneous cell populations using laser microdissection

Histology and histopathology, 2005-01, Vol.20 (1), p.139

2005

Volltextzugriff (PDF)

Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-positive Monocytes in Mice

The Journal of biological chemistry, 2003-11, Vol.278 (47), p.46654-46660

2003

Volltextzugriff (PDF)

Protamine-Modified DDAB Lipid Vesicles Promote Gene Transfer in the Presence of Serum

Journal of biochemistry (Tokyo), 2001-01, Vol.129 (1), p.125-132

2001

Volltextzugriff (PDF)

Identification of Dicarboxylate Carrier Slc25a10 as Malate Transporter in de Novo Fatty Acid Synthesis

The Journal of biological chemistry, 2005-09, Vol.280 (37), p.32434-32441

2005

Volltextzugriff (PDF)

Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development

Current molecular medicine, 2010-08, Vol.10 (6), p.596-607

2010

Volltextzugriff (PDF)

Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers

Genomics (San Diego, Calif.), 2009-10, Vol.94 (4), p.219-227

2009

Volltextzugriff (PDF)

Production of Transgenic Quails with High Frequency of Germ-Line Transmission Using VSV-G Pseudotyped Retroviral Vector

Biochemical and biophysical research communications, 2001-08, Vol.286 (3), p.456-463

2001

Volltextzugriff (PDF)

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

Cancer biology & therapy, 2010-04, Vol.9 (7), p.514-522

2010

Volltextzugriff (PDF)

Integrase-mediated nonviral gene transfection with enhanced integration efficiency

Journal of bioscience and bioengineering, 1999, Vol.88 (5), p.461-467

1999

Volltextzugriff (PDF)

Amplification of competitive telomere sequence in living animal cells induces chromatin instability

Cytotechnology (Dordrecht), 1999-09, Vol.31 (1-2), p.193-201

1999

Volltextzugriff (PDF)

Biomarker discovery by integrated joint non-negative matrix factorization and pathway signature analyses

Scientific reports, 2018-06, Vol.8 (1), p.9743-10, Article 9743

2018

Volltextzugriff (PDF)

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

Molecular cancer therapeutics, 2009-11, Vol.8 (11), p.2992-3000

2009

Volltextzugriff (PDF)

TAS2940, a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations

Cancer science, 2023-02, Vol.114 (2), p.654-664

2023

Volltextzugriff (PDF)

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways

Investigational new drugs, 2021-06, Vol.39 (3), p.724-735

2021

Volltextzugriff (PDF)

Role of the Toll-like Receptor 4/NF-κB Pathway in Saturated Fatty Acid–Induced Inflammatory Changes in the Interaction Between Adipocytes and Macrophages

Arteriosclerosis, thrombosis, and vascular biology, 2007-01, Vol.27 (1), p.84-91

2007

Volltextzugriff (PDF)

Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells

Cancer research (Chicago, Ill.), 2006-06, Vol.66 (12), p.6319-6326

2006

Volltextzugriff (PDF)

Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements

Human genetics, 2010-12, Vol.128 (6), p.567-575

2010

Volltextzugriff (PDF)

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

Clinical cancer research, 2011-05, Vol.17 (9), p.2799-2806

2011

Volltextzugriff (PDF)

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

Molecular cancer, 2009-06, Vol.8 (34), p.34-34, Article 34

2009

Volltextzugriff (PDF)

Inhibition of p70S6K2 down-regulates Hedgehog/GLI pathway in non-small cell lung cancer cell lines

Molecular cancer, 2009-07, Vol.8 (1), p.44-44, Article 44

2009

Volltextzugriff (PDF)

Abstract 3259: TAS3351 is a 4th-generation EGFR-TKI overcoming T790M and C797S-mediated resistance in NSCLC with EGFR common mutations

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3259-3259

2022

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(46)

Sprache

Englisch
(43)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(27)
Life Sciences & Biomedicine
(26)
Humans
(20)
Animals
(16)
Oncology
(12)
Biochemistry & Molecular Biology
(10)
Cell Line, Tumor
(10)
Tumors
(9)
Biological And Medical Sciences
(8)
Mice
(8)
Mutation
(8)
Cancer
(6)
Gene Expression Profiling
(6)
Male
(6)
Xenograft Model Antitumor Assays
(6)
Antineoplastic Agents
(5)
Female
(5)
Neoplasms - Genetics
(5)
Oligonucleotide Array Sequence Analysis
(5)
Proteins
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Gene expression-based pharmacodynamic biomarkers: the beginning of a new era in biomarker-driven anti-tumor drug development

433 Genomic predictors of therapeutic sensitivity to TAS-119, a selective inhibitor of Aurora-A kinase

438 Identification of Gene Expression Signature to Predict Anti-tumor Efficacy of MET/VEGFR Inhibitor, TAS-115

Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2

Advances in isolation and characterization of homogeneous cell populations using laser microdissection

Adiposity Elevates Plasma MCP-1 Levels Leading to the Increased CD11b-positive Monocytes in Mice

Protamine-Modified DDAB Lipid Vesicles Promote Gene Transfer in the Presence of Serum

Identification of Dicarboxylate Carrier Slc25a10 as Malate Transporter in de Novo Fatty Acid Synthesis

Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development

Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers

Production of Transgenic Quails with High Frequency of Germ-Line Transmission Using VSV-G Pseudotyped Retroviral Vector

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

Integrase-mediated nonviral gene transfection with enhanced integration efficiency

Amplification of competitive telomere sequence in living animal cells induces chromatin instability

Biomarker discovery by integrated joint non-negative matrix factorization and pathway signature analyses

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

TAS2940, a novel brain‐penetrable pan‐ERBB inhibitor, for tumors with HER2 and EGFR aberrations

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways

Role of the Toll-like Receptor 4/NF-κB Pathway in Saturated Fatty Acid–Induced Inflammatory Changes in the Interaction Between Adipocytes and Macrophages

Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells

Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

Inhibition of p70S6K2 down-regulates Hedgehog/GLI pathway in non-small cell lung cancer cell lines

Abstract 3259: TAS3351 is a 4th-generation EGFR-TKI overcoming T790M and C797S-mediated resistance in NSCLC with EGFR common mutations

Suchergebnisse filtern